Immune fitness and teclistamab response: MajesTEC-1 subanalysis

A subanalysis on the impact of immune fitness on response to teclistamab from MajesTEC-1 has been published in Blood by Cortes-Selva et al.¹ Researchers compared tumor characteristics and immune profiles of the 165 patients with relapsed/refractory multiple myeloma (RRMM) with response to 1.5 mg/kg teclistamab.

Key learnings:

There was a relationship identified between immune profiles and response to teclistamab.

Most notably, a higher baseline T-cell count in the peripheral blood was associated with improved response.

Patients who did not respond to teclistamab generally possessed immune profiles suggestive of immune suppression and T-cell dysfunction, with higher frequencies of T cells expressing exhaustion markers.

Increased progression-free survival rates were linked to lower frequencies of T cells with exhaustion markers at baseline.

These findings suggest that assessing baseline immune profiles could help predict response to teclistamab and aid in the development of personalized treatment plans.